BioSpace News Archive

Business

Replay Launches with $55M In Seed Funding To Author Genomic Medicine

Replay features next-generation genomic medicine technologies in its portfolio to address the needs of diseases that have large unmet needs.

July 25, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

WHO Declares Monkeypox a Public Health Emergency

The announcement signals that the WHO now views the outbreak as significant enough that a coordinated global response is necessary to control it.

July 25, 2022
·
4 min read
·
Mark Terry
Drug Development

Opposing Role of T-Cells in Promoting and Preventing Colorectal Cancers

A study published this month in Science discusses data that may support a devious alter ego of T-cells present within colorectal cancers that appear to inhibit and promote tumor progression.

July 25, 2022
·
2 min read
·
Jazmine Colatriano
Drug Development

FDA Hands Out Regulatory Nods to Novartis, AstraZeneca, HOOKIPA

Daiichi-Sankyo and AstraZeneca’s sBLA for HER2 directed Enhertu accepted by FDA. Novartis gets BLA acceptance for MS biosimilar. HOOKIPA’s IND for prostate cancer immunotherapy candidate accepted

July 25, 2022
·
4 min read
·
Tristan Manalac
FDA

Avadel Sues HHS and FDA for Not Approving Narcolepsy Drug

The complaint alleges the agencies made an error under the Administrative Procedure Act, violating the Food Drug and Cosmetics Act by failing to approve Lumryz.

July 25, 2022
·
3 min read
·
Mark Terry
Business

Zymergen Cuts 80 More Jobs Following Buyout by Ginkgo BioWorks - Updated

The transaction, Ginkgo’s largest acquisition to date, is expected to close by the first quarter of 2023, subject to regulatory approval and other closing conditions.

July 25, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Global Biotech News: Rona and Sanofi, Genuine Bio, and NEOsphere Bio

Here’s a look at global biopharma company news stories including Rona Therapeutics, Genuine Bio and NEOsphere Bio.

July 25, 2022
·
3 min read
·
Mark Terry
Deals

Biotech’s Prospects Transition from Hero to Zero and – Maybe – Back Again

The biotech industry is facing what some consider the worst times since its inception. Several market analysts recently shared their thoughts.

July 25, 2022
·
4 min read
·
Gail Dutton
Rona Therapeutics Announces Exclusive Licensing Transaction from Sanofi for its Broad siRNA Therapeutic Portfolio and Technology Platform

Rona Therapeutics, Inc announced that it has obtained worldwide exclusive rights to Sanofi’s siRNA platform of chemical modification and delivery moiety as well as rights to four pre-clinical candidates for undisclosed targets.

July 25, 2022
·
2 min read
Guillain-Barré Syndrome Market Trends, Business Strategy and Forecast

The global Guillain–Barré syndrome market was valued at US$ 454.0 Mn in 2016 and is expected to expand at a high CAGR of 5% from 2017 to 2025, to reach value of US$ 708.6 Mn by 2025, according to a new report published by Transparency Market Research

July 25, 2022
·
8 min read